Humacyte (HUMA) Share-based Compensation (2020 - 2026)

Humacyte (HUMA) has reported Share-based Compensation for 7 consecutive years, with $17.7 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Share-based Compensation rose 627.2% year-over-year to $17.7 million in Q2 2026; TTM through Jun 2026 was $17.7 million, a 116.73% increase from a year earlier, with the FY2025 full-year figure at $23.5 million, up 91.46% from the prior year.
• Share-based Compensation was $17.7 million for Q2 2026 at Humacyte, down from $21.0 million in the prior quarter.
• Over five years, Share-based Compensation peaked at $21.0 million in Q1 2026 and troughed at $1.4 million in Q4 2023.
• A 5-year average of $3.8 million and a median of $1.7 million in 2023 frame the typical range for Share-based Compensation.
• Across the five-year window, Share-based Compensation plunged 88.17% in 2022 and jumped 744.39% in 2026, its largest moves.
• Over 5 years, Share-based Compensation stood at $1.7 million in 2022, then slipped by 15.81% to $1.4 million in 2023, then advanced by 20.48% to $1.7 million in 2024, then soared by 84.65% to $3.1 million in 2025, then jumped by 465.86% to $17.7 million in 2026.
• The last three Share-based Compensation figures came in at $17.7 million (Q2 2026), $21.0 million (Q1 2026), and $3.1 million (Q4 2025), per Business Quant data.